<DOC>
	<DOCNO>NCT00233870</DOCNO>
	<brief_summary>The purpose survey identify concern regard follow efficacy safety-related issue clinical practice new drug `` Fabrazyme intravenous infusion 5mg '' `` Fabrazyme intravenous infusion 35mg '' confirm safety product long-term use clinical setting . 1 . New adverse drug reaction ( ADRs ) predict Precautions ( particular , clinically significant ADRs ) 2 . The incidence ADRs actual condition use drug 3 . Causal factor might potentially affect safety 4 . Efficacy evaluation long-term use This survey conduct accordance approval condition establish Fabrazyme : `` To conduct special surveillance Efficacy Safety long term treatment Pediatric drug . ''</brief_summary>
	<brief_title>A Long Term Safety Efficacy Study Fabrazyme Replacement Therapy Japanese Patients With Fabry Disease .</brief_title>
	<detailed_description>Medical institution physician ask periodically complete survey form patient register . Survey form include baseline information available , data collect every 6 month , available include : demographic information , concomitant medications/therapy , treatment record , ECG , Echocardiogram , compute tomography scan / magnetic resonance imaging ( CT/MRI ) , Fabry symptom , lab , functional disorder , blood concentration GL-3 , anti-agalsidase beta antibody test ( IgE test ) survey whether production antibody agalsidase beta causal factor treatment-related reaction . The survey period shall approximately 7 year June 1 , 2004 survey shall undertake follow : - The observation period patient shall range 1 7 year start treatment - Registration period : June 1 , 2004 March 31 , 2010 - Survey period : June 1 , 2004 March 31 , 2011 In institution retrospective survey feasible , survey period trace back date approval ( January 29 , 2004 ) , far possible .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Patients Japan indication `` Fabry Disease '' usual dosage administration 1mg agalsidase beta ( recombinant ) per 1 kg body weight time , administer intravenous infusion every 2 week Because efficacy evaluation enzyme replacement therapy Fabrazyme [ agalsidase beta ( recombinant form ) ] require comparison finding start enzyme replacement therapy , efficacy evaluation set define include patient use Fabrazyme [ agalsidase beta ( recombinant form ) ] first time postmarketing set possible obtain retrospective data start enzyme replacement therapy . Patients register postmarketing trial postmarketing clinical trial period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>